Results 231 to 240 of about 61,873 (295)
Some of the next articles are maybe not open access.
Tardive dyskinesia: Epidemiology
Journal of the Neurological Sciences, 2018The term tardive syndrome (TS) encompasses a few different phenomenologic conditions, some of which occur in isolation and others in association with each other. This, along with the unusual confound for a drug side effect, in which increased use of the drug improves the problem, and the need for most patients to continue taking the offending drug ...
Anelyssa, D'Abreu +2 more
openaire +3 more sources
Annual Review of Medicine, 1984
Although there are many published studies on the treatment of tardive dyskinesia (TD), relatively few treatments have proven to be consistently useful in clinical practice. Reviewed critically, most treatments have produced only slight to moderate benefit in less than half the patients treated.
C G, Goetz, H L, Klawans
+11 more sources
Although there are many published studies on the treatment of tardive dyskinesia (TD), relatively few treatments have proven to be consistently useful in clinical practice. Reviewed critically, most treatments have produced only slight to moderate benefit in less than half the patients treated.
C G, Goetz, H L, Klawans
+11 more sources
Seminars in Neurology, 2007
This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references.
Karla, Soares-Weiser +1 more
openaire +2 more sources
This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references.
Karla, Soares-Weiser +1 more
openaire +2 more sources
Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited
Neurogastroenterology and Motility, 2019Metoclopramide is primarily a dopamine receptor antagonist, with 5HT3 receptor antagonist and 5HT4 receptor agonist activity, and used as an antiemetic and gastroprokinetic since almost 50 years.
A. Al-Saffar +2 more
semanticscholar +1 more source
Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review
Journal of Psychopharmacology, 2019Background: It is commonly recommended that a switch to clozapine be implemented in the face of tardive dyskinesia, even if current treatment involves another “atypical” agent.
Parnian Pardis +4 more
semanticscholar +1 more source
Antipsychotic-induced tardive dyskinesia: update on epidemiology and management
Current Opinion in Psychiatry, 2019Purpose of review To provide an update on the frequency of antipsychotic-induced tardive dyskinesia and its management in patients with schizophrenia spectrum disorders in studies published since the last systematic review in 2008. Recent findings Recent
C. Widschwendter, A. Hofer
semanticscholar +1 more source
S.S. Korsakov Journal of Neurology and Psychiatry, 2023
Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non ...
openaire +2 more sources
Tardive dyskinesia (TD) is a delayed, often irreversible iatrogenic movement disorder caused by long-term use of that dopamine receptors blocking drugs. Prevention of TD is paramount, and clinicians should follow best practice recommendations for prescribing antipsychotics, as well as reduction the using of dopamine receptor blocking drugs for non ...
openaire +2 more sources
American Journal of Health-System Pharmacy, 1976
The etiology, pharmacology, treatment and possible prevention of tardive dyskinesia (TD) are discussed. This neurological disorder, characterized by involuntary movements of the lips, jaws and tongue, can occur as a result of short-term antipsychotic drug therapy, but usually occurs after long-term treatment.
K E, Clyne, R P, Juhl
openaire +3 more sources
The etiology, pharmacology, treatment and possible prevention of tardive dyskinesia (TD) are discussed. This neurological disorder, characterized by involuntary movements of the lips, jaws and tongue, can occur as a result of short-term antipsychotic drug therapy, but usually occurs after long-term treatment.
K E, Clyne, R P, Juhl
openaire +3 more sources
Current Treatment Options in Neurology, 2011
Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of ...
Pratibha G, Aia +3 more
openaire +2 more sources
Tardive dyskinesia (TD) is iatrogenic (drug-induced); hence the best strategy is prevention. Try to limit exposure to any dopamine receptor blocking agents (DRBAs) if possible. These agents may be unavoidable in some psychiatric conditions such as schizophrenia, but alternative therapies can be used in many situations, such as in the treatment of ...
Pratibha G, Aia +3 more
openaire +2 more sources